As Alexion, AstraZeneca Rare Disease, we are delivering life-changing therapies to people living with rare diseases.

Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

Jul 21, 2021 · AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the …

Dec 12, 2020 · Anglo-Swedish drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since …

5 days ago · “Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases,” said AZ’s chief executive Pascal Soriot.

Feb 6, 2025 · AstraZeneca ended development of vemircopan, triggering a $753 million charge as the drugmaker reevaluated the worth of its Alexion acquisition.

Alexion, AstraZeneca Rare Disease, is the rare disease focused group within AstraZeneca and was formed following the acquisition of Alexion Pharmaceuticals, Inc. in 2021.

Oct 8, 2025 · Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of …

As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.

Dec 12, 2020 · AstraZeneca, with Alexion's R&D team, will work to build on Alexion's pipeline of 11 molecules across more than 20 clinical-development programmes across the spectrum of …